187 related articles for article (PubMed ID: 24468886)
1. An assessment of the pharmacokinetics, pharmacodynamics, and tolerability of GCPGC, a novel pegylated granulocyte colony-stimulating factor (G-CSF), in healthy subjects.
Shin KH; Lim KS; Lee H; Jang IJ; Yu KS
Invest New Drugs; 2014 Aug; 32(4):636-43. PubMed ID: 24468886
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and Pharmacodynamics of Two Formulations of Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor in Healthy Chinese Subjects: An Open-Label, Randomized, Parallel-Design Bioavailability Study.
Hu C; Ji B; Hu X; Yang C; Sun W; Zhao X; Li L; Li X; Zhang L
Clin Pharmacol Drug Dev; 2021 Mar; 10(3):291-298. PubMed ID: 32567217
[TBL] [Abstract][Full Text] [Related]
3. Relationship between absolute neutrophil count profiles and pharmacokinetics of DA-3031, a pegylated granulocyte colony-stimulating factor (pegylated-G-CSF): a dose block-randomized, double-blind, dose-escalation study in healthy subjects.
Ahn LY; Shin KH; Lim KS; Kim TE; Jeon H; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
Clin Drug Investig; 2013 Nov; 33(11):817-24. PubMed ID: 24078278
[TBL] [Abstract][Full Text] [Related]
4. A Phase I study to determine safety, pharmacokinetics, and pharmacodynamics of ANF-RHO™, a novel PEGylated granulocyte colony-stimulating factor, in healthy volunteers.
Misra H; Berryman J; Jubin R; Abuchowski A
Invest New Drugs; 2018 Feb; 36(1):75-84. PubMed ID: 28752433
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of pegfilgrastim.
Yang BB; Kido A
Clin Pharmacokinet; 2011 May; 50(5):295-306. PubMed ID: 21456630
[TBL] [Abstract][Full Text] [Related]
6. A randomized, multicenter, phase II/III study to determine the optimal dose and to evaluate the efficacy and safety of pegteograstim (GCPGC) on chemotherapy-induced neutropenia compared to pegfilgrastim in breast cancer patients: KCSG PC10-09.
Lee KH; Kim JY; Lee MH; Han HS; Lim JH; Park KU; Park IH; Cho EK; Yoon SY; Kim JH; Choi IS; Park JH; Choi YJ; Kim HJ; Jung KH; Kim SY; Oh DY; Im SA
Support Care Cancer; 2016 Apr; 24(4):1709-17. PubMed ID: 26423618
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic and pharmacodynamic properties of a new long-acting granulocyte colony-stimulating factor (HM10460A) in healthy volunteers.
Shin KH; Kim TE; Lim KS; Yoon SH; Cho JY; Kim SE; Park KM; Shin SG; Jang IJ; Yu KS
BioDrugs; 2013 Apr; 27(2):149-58. PubMed ID: 23359067
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics and pharmacokinetics of single doses of subcutaneous pegylated human G-CSF mutant (Ro 25-8315) in healthy volunteers: comparison with single and multiple daily doses of filgrastim.
van Der Auwera P; Platzer E; Xu ZX; Schulz R; Feugeas O; Capdeville R; Edwards DJ
Am J Hematol; 2001 Apr; 66(4):245-51. PubMed ID: 11279634
[TBL] [Abstract][Full Text] [Related]
9. Lipegfilgrastim: pharmacodynamics and pharmacokinetics for body-weight-adjusted and 6 mg fixed doses in two randomized studies in healthy volunteers.
Buchner A; Lammerich A; Abdolzade-Bavil A; Müller U; Bias P
Curr Med Res Opin; 2014 Dec; 30(12):2523-33. PubMed ID: 25251999
[TBL] [Abstract][Full Text] [Related]
10. A Randomized, Double-Blind, Placebo- and Active-Controlled, Escalating Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Profiles of Subcutaneous Eflapegrastim in Healthy Japanese and Caucasian Subjects.
Jeon Y; Lee N; Baek S; Choi J; Jhee S; Lee H
Drugs R D; 2022 Mar; 22(1):71-87. PubMed ID: 34993933
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic and pharmacodynamic profile of new biosimilar filgrastim XM02 equivalent to marketed filgrastim Neupogen: single-blind, randomized, crossover trial.
Lubenau H; Bias P; Maly AK; Siegler KE; Mehltretter K
BioDrugs; 2009; 23(1):43-51. PubMed ID: 19344191
[TBL] [Abstract][Full Text] [Related]
12. Effect of escalating doses of recombinant human granulocyte colony-stimulating factor (filgrastim) on circulating neutrophils in healthy subjects.
Borleffs JC; Bosschaert M; Vrehen HM; Schneider MM; van Strijp J; Small MK; Borkett KM
Clin Ther; 1998; 20(4):722-36. PubMed ID: 9737832
[TBL] [Abstract][Full Text] [Related]
13. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy.
Johnston E; Crawford J; Blackwell S; Bjurstrom T; Lockbaum P; Roskos L; Yang BB; Gardner S; Miller-Messana MA; Shoemaker D; Garst J; Schwab G
J Clin Oncol; 2000 Jul; 18(13):2522-8. PubMed ID: 10893282
[TBL] [Abstract][Full Text] [Related]
14. Randomized controlled clinical trial of polyethylene glycol recombinant human granulocyte colony-stimulating factor in the treatment of neutropenia after chemotherapy for breast cancer.
Huang W; Liu J; Zeng Y; Wu F; Li N; Chen K; Hong Y; Wang L; Zhen H; Lin L
Cancer Chemother Pharmacol; 2018 Oct; 82(4):607-613. PubMed ID: 30043207
[TBL] [Abstract][Full Text] [Related]
15. PF-06881894, a Proposed Biosimilar to Pegfilgrastim, Versus US-Licensed and EU-Approved Pegfilgrastim Reference Products (Neulasta
Moosavi S; Borema T; Ewesuedo R; Harris S; Levy J; May TB; Summers M; Thomas JS; Zhang J; Yao HM
Adv Ther; 2020 Jul; 37(7):3370-3391. PubMed ID: 32524499
[TBL] [Abstract][Full Text] [Related]
16. Pegylated filgrastim is comparable with filgrastim as support for commonly used chemotherapy regimens: a multicenter, randomized, crossover phase 3 study.
Shi YK; Chen Q; Zhu YZ; He XH; Wang HQ; Jiang ZF; Chang JH; Liu YP; Wang AL; Luo DY; Zhang Y; Ke XY; Li WL; Zhang WJ; Wang XW; Zhang YP; Wang JM; Liu XQ
Anticancer Drugs; 2013 Jul; 24(6):641-7. PubMed ID: 23571496
[TBL] [Abstract][Full Text] [Related]
17. Randomized trial and pharmacokinetic study of pegfilgrastim versus filgrastim after dose-intensive chemotherapy in young adults and children with sarcomas.
Fox E; Widemann BC; Hawkins DS; Jayaprakash N; Dagher R; Aikin AA; Bernstein D; Long L; Mackall C; Helman L; Steinberg SM; Balis FM
Clin Cancer Res; 2009 Dec; 15(23):7361-7. PubMed ID: 19920107
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and pharmacodynamic modelling of the novel human granulocyte colony-stimulating factor derivative Maxy-G34 and pegfilgrastim in rats.
Scholz M; Engel C; Apt D; Sankar SL; Goldstein E; Loeffler M
Cell Prolif; 2009 Dec; 42(6):823-37. PubMed ID: 19780759
[TBL] [Abstract][Full Text] [Related]
19. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer.
Holmes FA; Jones SE; O'Shaughnessy J; Vukelja S; George T; Savin M; Richards D; Glaspy J; Meza L; Cohen G; Dhami M; Budman DR; Hackett J; Brassard M; Yang BB; Liang BC
Ann Oncol; 2002 Jun; 13(6):903-9. PubMed ID: 12123336
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy.
Lane SW; Crawford J; Kenealy M; Cull G; Seymour JF; Prince HM; Marlton P; Gill D; Mollee PN
Leuk Lymphoma; 2006 Sep; 47(9):1813-7. PubMed ID: 17064993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
